Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Gujarat Terce Laboratories Ltd Performance

Today's Low
62.73
arrowIcon
Today's High
64.01
52 Wk Low
16.65
arrowIcon
52 Wk High
70.91


Open

64.01

Traded Value (Cr)

65.55 K

Prev. Close

64.01

VWAP

62.73

Volume

1,045

Face Value

10

Gujarat Terce Laboratories Ltd Fundamentals

Market Cap
₹ 14 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
1.86
Debt to Equity
0.43
ROE
21.30 %
EPS (TTM)
0.00
Dividend Yield
0.00%
Book Value
10.32

Click here to know more about Fundamentals

Gujarat Terce Laboratories Ltd Financials

Gujarat Terce Laboratories Ltd Financials

Gujarat Terce Laboratories Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Retail 59.92 % 58.47 % 57.49 % 57.78 %
Promoters 37.03 % 37.01 % 36.78 % 36.65 %
Others 3.05 % 4.53 % 5.74 % 5.58 %
FII 0.00 % 0.00 % 0.00 % 0.00 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Retail

59.92%

Promoters

37.03%

Others

3.05%

FII

0.00%

Mutual Funds

0.00%

Retail

58.47%

Promoters

37.01%

Others

4.53%

FII

0.00%

Mutual Funds

0.00%

Retail

57.49%

Promoters

36.78%

Others

5.74%

FII

0.00%

Mutual Funds

0.00%

Retail

57.78%

Promoters

36.65%

Others

5.58%

FII

0.00%

Mutual Funds

0.00%

Resistance and Support

₹64.01

PIVOT

resistance-arrow
Resistance
First Resistance₹64.010
Second Resistance₹64.010
Third Resistance₹64.010
support-arrow
Support
First Resistance₹64.010
Second Resistance₹64.010
Third Resistance₹64.010
RSI47.626
MACD1.474
ADX32.813
CCI-24.051

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day1,9721,045100.00
Week2,4092,409100.00
1 Month17,05717,057100.00
6 Months000.00

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market. Over its more than three-decade business journey, the Company developed an extensive product basket comprising 50 brands covering multiple therapeutic areas which are marketed by its 180+ strong MR team across 13 Indian states. Headquartered in Ahmedabad, the Company has its fully automated facility at Chhatral, in Gandhinagar, Gujarat By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing. In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange. In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat. As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market. The Company is an ISO 9001 certified, WHO-GMP compliant operating facility manufactures world-class formulations and healthcare products that feature in acute and chronic therapeutic areas. It engaged into manufacture and sale of pharmaceutical formulations and ayurvedic medicines in India and internationally. It offers products in the form of tablets, capsules, syrups, and injections. The installed capacity of the Company is 270 million tablets and 108 million capsules per annum. The facility is ISO 9001 certified to manufacture world-class formulations and healthcare products for relief in acute and chronic therapeutic areas. The plant operates on the principles of Lean Manufacturing and Total Quality Management to reduces input costs and improve outcome efficiency. The plant is designed with dedicated HVAC system to prevent contamination and cross contamination. Terce has a separate facility to manufacture Cephalosporin antibiotics range. The Company otherwise or hence maintains strict and controlled environment for manufacturing and adheres to Good Manufacturing Practices and Good Laboratory Practices to assure highest level of patient safety and outcome efficacy. It has well-defined Total Quality Management System in place to continuously optimize products and processes. Each process is thoroughly monitored and data is collected for analysis which helps in planning corrective and preventive strategies for quality control. To serve the needs of patients and healthcare professionals, Company focus on early and rapid detection of diseases. Their team of scientists is supported by doctors, patients and marketing team in identifying pressing needs and developing solutions. It has capabilities of innovation across generic drugs to complex formulations, biosimilars and new molecular entity.

Managing Director

Aalap Prajapati

Founded

1985

NSE Symbol

Gujarat Terce Laboratories Ltd Management

NameDesignation
Amrutbhai P PrajapatiWhole-time Director
Chhayaben Ashwinbhai ShahIndependent Director
Viplav Suryakantbhai KhamarIndependent Director
Aalap PrajapatiManaging Director & CEO
Surendra Kumar SharmaIndependent Director
Navinchandra PatelIndependent Director
Natwarbhai P PrajapatiChairman & Wholetime Director

Gujarat Terce Laboratories Ltd News

Gujarat Terce Laboratories to hold EGM
On 25 April 2024
Gujarat Terce Laboratories to hold board meeting
On 29 March 2024
Gujarat Terce Laboratories reports standalone net profit of Rs 0.67 crore in the December 2023 quarter
Sales rise 9.41% to Rs 13.02 crore
Gujarat Terce Laboratories schedules board meeting
On 5 February 2024
Gujarat Terce Laboratories reports standalone net profit of Rs 0.33 crore in the September 2023 quarter
Sales decline 4.37% to Rs 12.03 crore
Gujarat Terce Laboratories to table results
On 8 November 2023
Gujarat Terce Laboratories reports standalone net loss of Rs 1.31 crore in the June 2023 quarter
Sales rise 13.92% to Rs 10.72 crore
Gujarat Terce Laboratories to table results
On 11 August 2023
Gujarat Terce Laboratories schedules AGM
On 25 August 2023
Gujarat Terce Laboratories reports standalone net profit of Rs 0.80 crore in the March 2023 quarter
Sales rise 38.30% to Rs 12.89 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,58,304 Cr
₹ 1,493.35
(-1.85 %)
86.97
CIPLA₹ 1,09,708 Cr
₹ 1,358.80
(-1.88 %)
33.36
DIVISLAB₹ 1,00,599 Cr
₹ 3,789.50
(-3.55 %)
73.75
DRREDDY₹ 98,073 Cr
₹ 5,879.05
(-2.93 %)
22.59
ZYDUSLIFE₹ 97,383 Cr
₹ 967.80
(-3.77 %)
36.23

Gujarat Terce Laboratories Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Gujarat Terce Laboratories Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Gujarat Terce Laboratories Ltd's share price is ₹62.73 as of May 9, 2024

Gujarat Terce Laboratories Ltd's P/E ratio is 0.00 times as of May 9, 2024.

Gujarat Terce Laboratories Ltd's most recent financial reports indicate a price-to-book ratio of 1.86, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Gujarat Terce Laboratories Ltd's market is 14 Cr as on May 9, 2024.

The current financial records of Gujarat Terce Laboratories Ltd show a 21.30% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Gujarat Terce Laboratories Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Gujarat Terce Laboratories Ltd's 52-week high and low as of May 9, 2024 are ₹64.01 and ₹62.73 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Gujarat Terce Laboratories Ltd stands at 37.03%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.